Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral can...
Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
About this item
Full title
Author / Creator
Ju, Wu‐tong , Liu, Ying , Wang, Li‐zhen , Li, Jiang , Ren, Guo‐xing , Sun, Jian , Tu, Wen‐yong , Hu, Yong‐jie , Ji, Tong , Yang, Wen‐jun , Li, Jun , He, Yue , Wang, Yan‐an , Zhang, Chen‐ping , Zhong, Lai‐ping and Zhang, Zhi‐yuan
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Due to the limited sample size of the clinical N2 group, our retrospective subgroup analyses were not sufficient to guide further treatment plan until further demonstrated by convincing studies. Besides clinical indicators, we also focused on the predictive effect of pathological response after induction chemotherapy. The pCR rate was consistent wi...
Alternative Titles
Full title
Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_bc8a63ae25d34d01a0aaf495a184cd65
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bc8a63ae25d34d01a0aaf495a184cd65
Other Identifiers
ISSN
2523-3548
E-ISSN
2523-3548
DOI
10.1002/cac2.12136
